Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas

Area of Science:

• Oncology
• Cancer Biology
• Neuroscience

Background:

• Glioblastoma multiforme (GBM) recurrence is linked to cancer stem-like cells (CSLCs).
• CSLCs are crucial drivers of tumor initiation and progression.
• Targeting CSLCs is a promising strategy for GBM treatment.

Purpose of the Study:

• To investigate the inhibitory effect of arsenic trioxide (As(2)O(3)) on GBM CSLCs.
• To evaluate As(2)O(3) efficacy in both in vitro and in vivo models.
• To elucidate the molecular mechanisms underlying As(2)O(3)-mediated CSLC inhibition.

Main Methods:

• Treatment of human glioma cell lines (U87MG, U251MG, U373MG) with As(2)O(3).
• Immunofluorescence staining and flow cytometry to assess Nestin-positive cells.
• Soft-agar assays and tumor xenograft models in nude mice.
• Western blot analysis for Notch1 and Hes1 protein levels.

Main Results:

• As(2)O(3) treatment significantly reduced Nestin-positive CSLCs in all tested cell lines.
• As(2)O(3) inhibited tumor formation in soft-agar and xenograft models.
• Western blot analysis showed decreased levels of Notch1 and Hes1 proteins following As(2)O(3) treatment.

Conclusions:

• Arsenic trioxide demonstrates significant inhibitory effects on glioblastoma cancer stem-like cells.
• The mechanism involves the negative regulation of CSLCs and deregulation of Notch activation.
• As(2)O(3) presents a potential therapeutic agent for glioblastoma treatment by targeting CSLCs.